Tissue Specimen News
-
Perimeter Medical Imaging AI Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of Wide-Field Optical Coherence Tomography (WF-OCT) in Head and Neck Surgeries
Perimeter Medical Imaging AI, Inc. (TSX-V: PINK)(OTC: PYNKF) (FSE: 4PC) (“Perimeter” or the “Company”) announced the publication of a peer-reviewed research article in JAMA Otolaryngology—Head and Neck Surgery. The study’s findings validate the further exploration of the use of Perimeter’s wide-field Optical Coherence Tomography (WF-OCT) technology to ...
-
Perimeter Medical Imaging AI and Pavilion Surgery Center Announce Placement of Perimeter S-Series OCT for Use at Ambulatory Surgery Center in Orange, CA
Pavilion Surgery Center, an affiliate of St. Joseph Hospital, along with Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”) – a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs – today jointly announced ...
-
Elucid Raises $27 Million Series B Funding Round to Commercialize a New Paradigm in Heart Disease Diagnosis
BOSTON – June 22, 2022 – Elucid, a company developing a novel, non-invasive medical software to comprehensively characterize cardiovascular disease, announced the closing of a $27 Million Series B financing round. The round was led by an undisclosed strategic investor, with participation from Biovision Ventures, a new Europe-based fund, and existing investors, including MedTex ...
By Elucid
-
Foundation Medicine Announces Global Collaboration With Lilly to Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for RETEVMO® and Loxo Oncology at Lilly’s Pipeline Programs
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. today announced a collaboration with Eli Lilly and Company (Lilly) for the development of Foundation Medicine’s tissue- and blood-based assays as companion diagnostics for RETEVMO® and other therapies in Loxo Oncology at Lilly’s pipeline. The partnership will initially explore the use of FoundationOne®CDx for adult ...
-
Perimeter Medical Imaging AI Announces Initiation of Additional Clinical Trial Site at Baylor College of Medicine in Houston, TX
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, announced the expansion of its ongoing pivotal study to include an additional clinical trial site at Baylor ...
-
Perimeter Medical Imaging AI Announces First Commercial Installation of Perimeter S-Series OCT in North Texas and Ongoing Market Development Activities Across the U.S.
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced the first commercial installation of its flagship Perimeter S-Series OCT system at a North ...
-
Perimeter Medical Imaging AI Announces Initiation of First Clinical Trial Site at West Cancer Center & Research Institute in Tennessee
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, announced the initiation of a multi-center, randomized, two-arm pivotal clinical trial to evaluate its ...
-
FoundationOne®CDx Receives FDA Approval as a Companion Diagnostic for BRAF Inhibitor Therapeutics in Melanoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic for two groups of current and future FDA-approved therapeutics in melanoma, which includes BRAF inhibitor monotherapies targeting BRAFV600E and BRAF/MEK inhibitor combination ...
-
Perimeter Medical Imaging AI Announces Important Milestone in ATLAS AI Project With FDA Investigational Device Exemption (IDE) Approval to Launch Clinical Trial Using Perimeter B-Series OCT With ImgAssist AI in Breast Conservation Surgery
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced approval of its Investigational Device Exemption (“IDE”) application by the U.S. ...
-
Foundation Medicine Now an In-Network Provider for Humana Military and Health Net Federal Services
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. today announced that the company has signed agreements for in-network provider status with Humana Military and Health Net Federal Services, which administer the TRICARE health program for military members, retirees and their families (TRICARE).1,2 TRICARE is one of the largest health plans in the United States with 9.6 million ...
-
Invenio Imaging Celebrates 2000th NIO Laser Imaging System case
SANTA CLARA, Calif., Oct. 12, 2021 /PRNewswire/ -- Invenio Imaging is proud to announce the 2000th case with the NIO Laser Imaging System, which uses Stimulated Raman Histology to provide microscopic images of fresh tissue specimens in minutes. NIO images can be shared digitally for immediate review by pathology, allowing closer collaboration between surgery and pathology. "As ...
-
Invenio Imaging receives CE Mark for NIO Laser Imaging System
SANTA CLARA, Calif., Sept. 28, 2021 /PRNewswire/ -- Invenio Imaging announced today that it has obtained the CE Mark for the NIO Laser Imaging System according to the In Vitro Diagnostic Directive (IVDD). This enables commercialization of this novel imaging system for intraoperative histology in the European market. The NIO Laser Imaging System uses Stimulated Raman Histology to ...
-
Perimeter Medical Imaging AI Provides Corporate Update on Ramp-Up of its Commercial Organization
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today provided a corporate update on the progress made to date to grow its commercial organization. Under the ...
-
Perimeter Medical Imaging AI to Participate in Panel Discussion “Innovations in Breast Cancer Detection, Surgery and Treatment” at the Lytham Partners Summer 2021 Investor Conference
Perimeter Medical Imaging AI, Inc. (TSX-V: PINK)(OTC: PYNKF)(FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced that the Company's Chief Executive Officer, Jeremy Sobotta, will participate in a panel at the ...
-
Ambra Health and Invenio Imaging Partner to Provide Pathologists Instant Access to Medical Imaging
NEW YORK— JULY 16, 2020 — Ambra Health, makers of the leading cloud-based, medical image management suite and Invenio Imaging, a leader in rapid intraoperative tissue imaging with Stimulated Raman Histology (SRH), today announced a partnership that integrates Ambra’s image management technology with Invenio’s NIO Laser Imaging System. The collaboration enables pathologists ...
-
Thermo Fisher Scientific to Co-develop a Global Companion Diagnostic for Low-grade Glioma with Agios Pharmaceuticals
Thermo Fisher Scientific today announced that it has expanded its strategic partnership with Agios Pharmaceuticals by adding the co-development of a second companion diagnostic (CDx) for oncology to their existing agreement. The CDx will leverage the Oncomine Precision Assay, which runs on the new Ion Torrent Genexus System, and will be used globally to identify low-grade glioma (LGG) patients ...
-
VeraForm® Proving Itself Across Multiple Imaging Platforms
Tomosynthesis imaging is a critical technology in the treatment of breast cancer and 3-D intraoperative specimen imaging is state-of-the art. The MOZART® System from KUBTEC Medical Imaging stands alone as it identifies the exact location of three dimensional objects such as tumors and localization devices inside breast cancer specimens. The VeraForm adaptable tissue marker is a radiopaque, ...
-
Brady introduces specimen labeling solution for histology and anatomic pathology labs
Brady Worldwide, Inc. (NYSE: BRC), a trusted provider for laboratory labeling, is pleased to introduce a new specimen labeling system for histology and anatomic pathology labs – the Brady Specimen Labeling Solution. With a revolutionary label attachment system and durable labels that withstand tissue processing and last up to 20 years in storage, Brady’s Specimen Labeling Solution is an ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you